CareDx, Inc.
CDNA
$48.61
+3.45%
CareDx, Inc. is a precision medicine company that develops, manufactures, and commercializes diagnostic tests and digital solutions for transplant patients, operating in the medical diagnostics and research industry. It is a market leader in transplant diagnostics, offering a comprehensive portfolio including AlloSure Kidney, AlloMap Heart, and other dd-cfDNA-based tests that monitor organ health. The current investor narrative centers on the company's strategic pivot to its high-margin core testing services, following the divestiture of its lower-growth Lab Products division, and its impressive Q2 2026 earnings beat with raised full-year guidance, which has fueled a significant rally in the stock.…
CDNA
CareDx, Inc.
$48.61
Related headlines
Investment Opinion: Should I buy CDNA Today?
Rating: Buy. CareDx is a high-growth diagnostics company with a strong strategic position in transplant testing. The consensus analyst rating is 'buy' with an average target of $52.33, implying 7.7% upside. The thesis is supported by revenue growth of 288.6% in the past year, a gross margin of 67.6%, and a PEG ratio of 0.34, indicating undervaluation relative to growth.
Sign up to view all
CDNA 12-Month Price Forecast
The AI assessment is bullish on CareDx, driven by its exceptional growth, high gross margins, and favorable valuation on a PEG basis. The company's strategic focus on high-margin testing services positions it well for continued expansion. However, the negative net margin and high beta warrant caution. If the company achieves profitability and maintains growth, the stock could re-rate higher. Conversely, any signs of growth deceleration or margin compression would lead to a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareDx, Inc.'s 12-month outlook, with a consensus price target around $52.33 and implied upside of +7.7% versus the current price.
Average Target
$52.33
0 analysts
Implied Upside
+7.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $64
Analyst target range
Analyst coverage is limited with only 6 analysts, but the consensus recommendation is a 'buy' with a mean rating of 1.86 (where 1 is strong buy and 5 is sell). The average target price is $52.33, implying an upside of 7.7% from the current price of $48.61. The target price range is wide, from a low of $40.00 to a high of $64.00, indicating significant uncertainty about the company's future performance. The high target suggests expectations of continued strong growth and margin expansion, while the low target reflects concerns about competitive pressures or execution risks. The limited coverage may contribute to higher volatility and less efficient price discovery.
Bulls vs Bears: CDNA Investment Factors
CareDx presents a compelling growth story with explosive revenue growth, high gross margins, and a strategic pivot to high-margin testing services. The bull case is supported by a PEG ratio of 0.34 and strong analyst buy ratings, while the bear case highlights negative net margins, premium valuation, and high volatility. Currently, the bull case has stronger evidence given the company's momentum and strategic clarity, but the key tension lies in whether the company can translate its high gross margins into net profitability. If CareDx achieves sustained profitability, the stock could re-rate higher; if not, the premium valuation could compress significantly.
Bullish
- Explosive Revenue Growth: CareDx's most recent quarterly revenue is estimated at $591 million (annualized), reflecting a significant expansion driven by its core testing services. This growth trajectory is a key driver of the stock's 288.6% surge over the past year.
- High Gross Margin of 67.6%: The company's gross margin stands at 67.6%, indicating a highly profitable core business model. This high margin provides a strong foundation for future profitability as the company scales.
- Strategic Pivot to Core Testing: CareDx divested its lower-growth Lab Products division to focus on high-margin testing services, a move that sharpened its growth profile. This strategic shift is already reflected in the Q2 2026 earnings beat and raised guidance.
- Undervalued on PEG Ratio: With a PEG ratio of 0.34, the stock appears undervalued relative to its growth prospects. This suggests that the market may not be fully pricing in the company's future earnings potential.
Bearish
- Negative Net Margin: Despite strong gross margins, CareDx's net margin is -5.6%, indicating the company is not yet profitable. This raises concerns about its ability to achieve sustained profitability and justify its valuation.
- High Valuation on PS Ratio: The price-to-sales ratio of 2.64x is at a premium to the industry average, which could limit upside if growth decelerates. Investors are paying a premium for expected growth, leaving little room for error.
- Limited Analyst Coverage: With only 6 analysts covering the stock, there is less scrutiny and potentially higher volatility. The wide target range ($40-$64) reflects significant uncertainty about future performance.
- Overbought Technicals: The stock is trading near its 52-week high at 97.7% of the high, suggesting it may be overextended in the short term. The 288.6% one-year gain could invite profit-taking.
CDNA Technical Analysis
CareDx is in a powerful sustained uptrend, with the stock price surging 288.6% over the past year, dramatically outperforming the S&P 500's 20.5% gain. The current price of $48.61 sits near the top of its 52-week range, at 97.7% of the high of $49.76, indicating strong momentum and bullish sentiment, though it also suggests the stock may be overextended in the short term. The stock is trading well above its 52-week low of $12.28, reflecting a massive recovery from previous lows.
Beta
2.42
2.42x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$12-$50
Price range past year
Annual Return
+288.6%
Cumulative gain past year
| Period | CDNA Return | S&P 500 |
|---|---|---|
| 1m | +28.7% | +3.6% |
| 3m | +124.7% | +2.7% |
| 6m | +158.6% | +11.4% |
| 1y | +288.6% | +18.7% |
| ytd | +154.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CDNA Fundamental Analysis
CareDx's revenue is on a strong growth trajectory, with the most recent quarterly revenue estimated at $591 million (annualized), reflecting a significant expansion driven by its core testing services. The company's gross margin is robust at 67.6%, indicating a high-margin business model, though its net margin is currently negative at -5.6%, showing that the company is not yet profitable on a net basis. However, the company is making progress toward profitability, with operating margin at -6.6%, and the negative EPS of -$0.02 per share is narrowing, suggesting improving operational efficiency.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CDNA Overvalued?
Given that CareDx has negative trailing net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and it currently stands at 2.64x, which is reasonable for a high-growth diagnostics company. The forward PE of 35.9x implies that the market expects significant earnings growth, and the PEG ratio of 0.34 suggests that the stock may be undervalued relative to its growth prospects. Compared to the industry average, CareDx's PS ratio is at a premium, but this is justified by its superior growth and market position in transplant diagnostics.
PE
-47.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-207.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CareDx's negative net margin of -5.6% and operating margin of -6.6% indicate that the company is not yet profitable, which poses a risk if growth slows. The company's debt-to-equity ratio is low at 0.086, but its negative EPS of -$0.02 per share shows it is still burning cash. Revenue concentration in testing services, while strategic, exposes the company to reimbursement and regulatory risks. The current ratio of 2.86 provides liquidity, but sustained losses could erode this buffer.